Table S4.
Regimens
| Regimens | First-line | Second-line | Third-line |
|---|---|---|---|
| N | 103 | 63 | 32 |
| Platinum-based | 92 | 4 | 4 |
| Platinum | |||
| Cisplatin-based | 1 | 0 | 1 |
| Carboplatin-based | 91 | 4 | 3 |
| Partner agent | |||
| Paclitaxel | 52 | 2 | 2 |
| nab-Paclitaxel | 16 | 1 | 0 |
| S-1 | 18 | 1 | 1 |
| Gemcitabine | 3 | 0 | 0 |
| Docetaxel | 3 | 0 | 0 |
| Vinorelbine | 0 | 0 | 1 |
| Non-platinum doublets | |||
| Docetaxel + S-1 | 0 | 6 | 0 |
| Gemcitabine + vinorelbine | 0 | 2 | 9 |
| Non-platinum monotherapy | |||
| Docetaxel | 0 | 33 | 6 |
| EGFR-TKI | 0 | 12 | 7 |
| S-1 | 10 | 6 | 6 |
| Gemcitabine | 1 | 0 | 0 |
| Concurrent thoracic radiotherapy | 8 | 0 | 1 |
Note: Data are presented as number of patients.
Abbreviation: EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.